SPONSOR
Gruppo Oncologico del Nord-Ovest
Total Trials
2
Recruiting
2
Phases
Phase 2
Conditions studied: Colorectal CancerColorectal AdenocarcinomaRectal AdenocarcinomaRectal Cancer, AdenocarcinomaRectal Cancer, MetastaticColon Cancer MetastaticColon Cancer AdenocarcinomaHead & Neck Squamous Cell Carcinoma
NCT07407465 Phase 2
Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Colorectal Cancer
NCT07485296 Phase 2
Recruiting
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)
Head & Neck Squamous Cell Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology